Niva Bupa Health Insurance Valuation and Stock Price Analysis Aug 2026

Zumedha Insights
Research . Analysis . Insights
Fairly Valued ₹87.65 as on 04 Aug 2026

Niva Bupa Health Insurance Co. Ltd.

India’s fastest-growing standalone health insurer scaling toward underwriting profitability — a growth story priced for successful execution rather than a value opportunity at current levels.
NSENIVABUPA
BSE544286
ISININE995S01015
Face Value₹10
52W High/Low₹92.9 / ₹67.5
Mkt Cap₹16,190 Cr
Shares O/S184.7 Cr
IndexNifty 500, Smallcap 250
Promoter Holding55.36% (Bupa)
CMP
₹87.65
Mkt Cap
₹16,190 Cr
52W H/L
92.9/67.5
P/E (I-GAAP)
123.5x
GWP (FY26)
₹9,433 Cr
PAT (IFRS)
₹366 Cr
Solvency Ratio
2.49x
01 / BUSINESS OVERVIEW

Business Overview

Niva Bupa Health Insurance Company Ltd (formerly Max Bupa) is a New Delhi-headquartered standalone health insurer (SAHI), incorporated in 2008 and operational since March 2010. It is a joint venture between UK-based Bupa (55.36% promoter stake) and Indian private equity investor True North, and listed on the NSE/BSE in November 2024 via a ₹2,200 Cr IPO. The company held a gross direct premium income (GDPI) market share of roughly 5.3% of the overall health insurance segment and about 17.6% among standalone private health insurers in FY25; its retail health market share has since improved to approximately 10.1% by FY26.

The business is organised around retail products (individuals and families — flagship plans ReAssure and Health Premia) and group products (employers, banks, and corporate agents), supplemented by personal accident and travel insurance. Distribution is diversified across individual agents (~30%), brokers (~30%), corporate agents (~30%) and direct/digital channels (~10%), supported by a network of 10,000+ hospitals offering cashless claims and roughly 25.2 million active lives insured as of FY26. Krishnan Ramachandran serves as MD & CEO; Ashwani Bhatia has been named incoming Chairperson (effective June 2026, subject to IRDAI approval), succeeding C.B. Bhave.

Active Lives Insured
25.2 Mn
Network Hospitals
10,000+
Retail Health Mkt Share
~10.1%
Claims Settlement Ratio
94.4%
02 / HISTORICAL FINANCIALS

Historical Financials (I-GAAP)

Niva Bupa has compounded revenue at roughly 36% CAGR over five years and turned consistently profitable only from FY23 onward, as the retail book scaled and loss ratios stabilised. FY26 I-GAAP net profit fell to ₹131 Cr from ₹214 Cr in FY25 — a decline explained mainly by a sharp drop in “other income” (₹160 Cr to ₹2 Cr) and a one-off ₹20 Cr Code on Social Security impact recognised in 9M FY26, not by a deterioration in underlying underwriting economics.

₹ CrFY22FY23FY24FY25FY26
Revenue (Sales)1,8772,8534,1155,3746,695
Operating Profit-451-330-11378125
OPM %-24%-12%-3%1%2%
Net Profit (I-GAAP)-1971382214131
Net Profit (IFRS)——106203366
EPS I-GAAP (₹)———1.170.71

Data integrity note: Niva Bupa reports both I-GAAP (regulatory) and IFRS financials, and the two diverge materially due to differences in investment income and deferred acquisition cost recognition. I-GAAP PAT fell 39% YoY in FY26 while IFRS PAT rose 80% YoY to ₹366 Cr — this analysis treats IFRS PAT as the better proxy for economic earnings power, while I-GAAP book value and solvency remain the basis for regulatory capital assessment.

5Y Sales CAGR
36%
3Y Profit CAGR
127%
ROE (FY26)
3.8%
ROCE (FY26)
3.5%
03 / DCF VALUATION (RESIDUAL INCOME FRAMEWORK)

DCF / Excess-Return Valuation

Insurers do not generate conventional free cash flow — earnings are retained as regulatory capital rather than distributed, and value is driven by the spread between return on equity and cost of equity. In place of an FCFF-DCF, this analysis uses a Residual Income (Excess Return) model: Fair P/B = 1 + (ROE − g) / (Ke − g), applied to book value per share.

Residual Income Model — Base Case

Cost of Equity (Ke)13.5%
Steady-state sustainable ROE15.0%
Long-term growth (g)12.0%
Implied Fair P/B3.0x
Book Value per Share (FY26)₹20.5
Base-case Fair Value₹62

At the current CISR trajectory (101.4% FY26, 97.4% in Q4 alone) and a 25%+ GWP growth guidance, a bull case assuming ROE scales to ~18% on a mature underwriting book would push fair P/B materially higher; a bear case where CISR remains sticky above 100% and ROE stays near 10% pulls fair value toward book value. The wide dispersion below reflects how sensitive this valuation is to the pace of underwriting-margin improvement.

04 / RELATIVE VALUATION

Relative Valuation & Peer Multiples

Price-to-book is the more meaningful cross-sectional metric for insurers than P/E, given accounting-driven earnings volatility. On P/B, Niva Bupa trades broadly in line with Star Health (its closest standalone health-insurer peer) but at a materially lower ROE, while composite insurer ICICI Lombard commands a higher P/B justified by a higher, more stable ROE profile.

CompanyMkt Cap (₹Cr)P/E (x)P/B (x)ROE (3Y avg)
Niva Bupa Health Insurance16,190123.5 (I-GAAP) / 44.0 (IFRS)4.28~6%
Star Health & Allied Insurance~34,900~55–62~4.1–4.6~7.5–9.7%
ICICI Lombard General Insurance~83,600~34–35~5.3–6.1~15–17%*

*ICICI Lombard is a diversified composite (motor/fire/health) insurer, not a pure health peer; included for benchmarking scale and margin maturity only.

Applying a peer-anchored P/B band of 4.0x–4.6x (Star Health range) to Niva Bupa’s FY26 book value of ₹20.5 implies a relative-valuation fair range of roughly ₹82–₹94 — broadly consistent with, and slightly above, the residual-income base case, suggesting the market is already pricing a Star-Health-like maturity outcome.

05 / ASSET-BASED / NAV

Asset-Based / NAV Valuation

Net worth stood at ₹3,786 Cr as of March 2026 (equity capital ₹1,847 Cr + reserves ₹1,939 Cr) against 184.7 Cr shares, giving a book value of ₹20.5 per share. This represents the pure liquidation/regulatory-capital floor with zero credit given to franchise value or growth optionality — the stock currently trades at 4.28x this floor.

Net Worth (FY26)
₹3,786 Cr
Book Value/Share
₹20.5
AUM (Investments)
₹9,670 Cr
Investment Yield
7.2%
06 / EARNINGS POWER VALUE

Earnings Power Value (EPV)

EPV capitalises current, normalised earnings at the cost of equity with no credit for future growth — a useful “no-growth floor.” Using FY26 IFRS PAT of ₹366 Cr capitalised at a 13.5% cost of equity:

Earnings Power Value

Normalised IFRS PAT (FY26)₹366 Cr
Cost of Equity13.5%
Implied Equity Value₹2,711 Cr
EPV per Share₹15

The gap between this ₹15 no-growth floor and the ₹87.65 CMP illustrates that essentially all of Niva Bupa’s current market value rests on the market’s confidence in continued 20–25%+ premium growth and further margin expansion — this is a growth stock, not an earnings-power value stock, at today’s price.

07 / SUM-OF-THE-PARTS

Sum-of-the-Parts

As a single-line health insurer, a conventional multi-segment SOTP does not apply. Instead, value is decomposed into (a) the core underwriting franchise on a residual-income basis, (b) the value of surplus regulatory capital held above the 1.5x solvency minimum, and (c) an optionality premium for India’s under-penetrated retail health market.

Component₹/ShareBasis
Core underwriting franchise58Residual income, steady-state ROE 15%
Surplus solvency capital62.49x actual vs 1.5x regulatory minimum
Growth optionality (retail health penetration)18Qualitative premium for runway & Bupa parentage
SOTP Fair Value82
08 / BUY RANGE

Buy Range

Strong Buy
Below ₹62
Accumulate
₹62 – ₹75
Fair Value
₹75 – ₹90

CMP of ₹87.65 sits at the upper edge of the fair-value band — not a compelling entry point on a risk-adjusted basis unless one has high conviction in a sustained shift to sub-100% combined ratios.

09 / BUY SCENARIO

Buy Scenario

Bear

₹45–50

CISR stays above 100%, group loss ratio keeps rising, growth slows below 15%, ROE stuck near 5–7%.

Base

₹62–68

CISR glides to ~97–98%, ROE reaches low-teens by FY28, growth moderates to ~18–20%.

Bull

₹85–95

CISR sustainably below 95%, ROE scales to high-teens, retail share gains continue, no near-term capital raise needed.

10 / SELL RANGE

Sell Range

Reduce
₹92 – ₹102
Exit
₹102 – ₹112
Avoid Fresh Buys
Above ₹112
11 / SELL SCENARIO

Sell Scenario

Overvalued

>₹105

Stock re-rates further on momentum despite no fresh improvement in underwriting metrics — multiple expansion outruns fundamentals.

Exit Trigger

CISR >103% for 2 quarters

Reversal in the combined-ratio improvement trend, or solvency ratio falling toward 1.8–2.0x forcing a dilutive capital raise.

Structural Break

Regulatory/parent risk

Adverse IRDAI commission/expense-of-management rule changes, or Bupa reducing strategic commitment/stake.

12 / FUTURE GROWTH

Future Growth

Management guides for continued ~25% GWP growth, targeting ₹15,000–16,000 Cr of GWP within 2–3 years from ₹9,433 Cr in FY26. Retail health GWP grew 35% YoY in FY26, well ahead of the group book, and the company continues to expand distribution depth across individual agency, brokers, and bancassurance-style corporate-agent tie-ups. India’s health insurance penetration remains low relative to GDP, leaving a long runway; further operating leverage as the CISR trends below 100% (already 97.4% in Q4 FY26) should be the key driver of ROE expansion over FY27–29, alongside cross-sell of travel and personal accident products to the existing 25 million-plus active-lives base.

13 / RISKS & CATALYSTS

Risks & Catalysts

Bull Case Drivers

  • CISR improved 160 bps YoY to 101.4% in FY26, with Q4 already at 97.4% — a clear inflection toward underwriting profitability.
  • Strong parent support: Bupa (55.4% stake) and AAA-rated (ICRA) issuer profile.
  • Large structural runway — India’s retail health insurance penetration remains among the lowest globally.
  • Rising FII/DII ownership (combined ~27% by Mar 2026, up from ~18.7% in Dec 2024) signals institutional conviction.
  • Improving customer metrics — NPS up to +60 (FY26) from +55 (FY25), claims settlement ratio 94.4%.

Bear Case Risks

  • Solvency ratio declined from 3.03x (FY25) to 2.49x (FY26) as growth consumes capital — still well above the 1.5x minimum, but the buffer is shrinking.
  • Group loss ratio rose from 57% to 62% due to business-mix shift; retail loss ratio stable but elevated at ~67%.
  • Single-line concentration risk in health insurance, unlike diversified composite peers.
  • Valuation is already rich on most metrics (4.28x P/B, EPV floor of just ₹15/share) — vulnerable to de-rating on any growth or margin disappointment.
  • Governance transition — incoming Chairperson (Ashwani Bhatia) pending IRDAI approval; regulatory changes to commission/expense-of-management caps remain a watch item.
Fairly Valued — Growth Priced In

Verdict

Weighing the residual-income base case (~₹62), the SOTP estimate (~₹82), and the peer-relative band (~₹82–94) against a CMP of ₹87.65, this analysis suggests Niva Bupa is trading close to the upper end of a reasonable fair-value range rather than offering a margin of safety. The investment case rests almost entirely on execution of the combined-ratio glide-path already underway (101.4% FY26, 97.4% in Q4) converting into sustained double-digit ROE over the next two to three years; the EPV floor of roughly ₹15/share is a reminder of how much of the current price is optionality rather than proven earnings power. Existing holders riding the underwriting-profitability turnaround and India’s health-insurance growth runway have reasonable grounds to stay invested with a multi-year horizon; fresh capital would be better deployed either in the ₹62–75 accumulate zone on a pullback, or after two to three consecutive quarters of sub-100% combined ratios provide firmer evidence that the ROE inflection is durable rather than seasonal.

Disclaimer: This report is prepared by Zumedha Insights for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer/solicitation to buy or sell any security. Figures are sourced from company filings, exchange disclosures, credit-rating agency reports, and third-party financial data providers as of early August 2026 and may be subject to revision. Insurance-specific valuation approaches (residual income, EPV, SOTP) involve significant assumptions around cost of equity, sustainable ROE, and growth that materially affect output; readers should treat all fair-value estimates as illustrative ranges, not price targets. Past performance is not indicative of future results. Please conduct independent due diligence or consult a SEBI-registered investment advisor before making investment decisions.

Hot this week

HDFC Bank Technical Analysis November 2026

HDFC Bank closed at ₹788.25 on 6 Nov 2026, up about 17.8% from its 52-week low. This technical analysis covers moving averages, RSI, MACD, pivots, Fibonacci levels, volume and scenarios using cross-checked data

What Is Fundamental Analysis of a Stock? Complete Guide with Example

Fundamental analysis estimates what a company's shares are truly worth by studying its business, financial statements and growth outlook. This guide covers the key ratios, valuation methods and a step-by-step worked example

Aster DM Quality Care (ASTERDM) stock Analysis November 2026

Aster DM Quality Care’s merger with Quality Care India created a 39-hospital, ~10,600-bed platform. This analysis weighs five valuation methods, news and sentiment to estimate a fair value of ₹514 against a CMP of ₹719.55

Asian Paints Share Price Target, Fundamental & Technical Analysis November 2026

Asian Paints (NSE: ASIANPAINT) fundamental and technical analysis after Q2 FY27: five valuation methods, a weighted fair value of ₹1,493 against a CMP of ₹2,523.80, buy and sell ranges, risks, and key support and resistance levels

Marico Ltd (NSE: MARICO) Share Price Target 2026: Stock Analysis & Fair Value

Marico's Q2 FY27 brought 10% India volume growth, 27% EBITDA growth and raised FY27 guidance. This Zumedha analysis values the stock with DCF, peer multiples, NAV, EPV and SOTP, and arrives at a Weighted Fair Value of ₹583 against a CMP of ₹878, with buy and sell ranges, scenarios and risks

Topics

Zydus Lifesciences Ltd Share Price Analysis April 2026

Zydus Lifesciences — Investment Research Report:root { ...

Cyient Ltd DCF Valuation Share Price April 2026

Cyient Ltd — Equity Research | Zumedha:root { ...

Tata Capital Share Price Analysis April 2026

Tata Capital — Zumedha Insights:root { ...

Syngene International Stock Price Analysis May 2026

@import url('https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;0,900;1,400;1,600&family=Source+Serif+4:ital,opsz,wght@0,8..60,300;0,8..60,400;0,8..60,600;1,8..60,300;1,8..60,400&family=IM+Fell+English+SC&family=JetBrains+Mono:wght@400;500;600&display=swap');.zumedha-syngene-report { --ink: #1a1a2e; --ink-light: #2d2d44; ...

Bandhan Small Cap Fund-March 2026 Analysis

.bsc-wrap { font-family: 'Lato', sans-serif; margin: 0 auto; color:...

HDFC Mid-Cap Opportunities Fund Analysis April 2026

@import url('https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;0,900;1,400;1,600&family=Source+Serif+4:ital,opsz,wght@0,8..60,300;0,8..60,400;0,8..60,600;1,8..60,300;1,8..60,400&family=IM+Fell+English+SC&family=JetBrains+Mono:wght@400;500;600;700&display=swap');.zumedha-report * { box-sizing: border-box; margin: 0; padding:...

DCF Valuation Method: Formula, Steps, Examples & Uses

DCF valuation explained step by step: the formula, FCFF vs FCFE, WACC, terminal value, a worked numerical example, sensitivity analysis, reverse DCF and where the method works or fails for Indian stocks.

Related Articles